Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis
Mary G Boy,Cunshan Wang,Bethanie E Wilkinson,Vincent Fung-Sing Chow,Alan T Clucas,James G Krueger,Anderson S Gaweco,Samuel H Zwillich,Paul S Changelian,Gary Chan
DOI: https://doi.org/10.1038/jid.2009.25
IF: 7.59
2009-01-01
Journal of Investigative Dermatology
Abstract:TO THE EDITOR Aberrant activation of the cellular immune system is recognized as the driving pathogenic event of psoriasis (Krueger and Bowcock 2005), confirmed by an infiltration of T-cells into psoriatic lesions (Gudjonsson et al 2004). Inhibition of Janus kinase 3 (JAK3) in T cells is expected to uncouple early T-cell receptor-triggered signaling from downstream events (Pesu et al 2005) and, for this reason, JAK3 inhibitors could be effective in T-cell-mediated disorders such as psoriasis. CP-690,550 is an orally active highly selective JAK inhibitor and potent inhibitor of JAK3, being developed as an immunosuppressive treatment for autoimmune diseases and for the prevention of allograft rejection (Changelian et al 2003). Repeat doses of CP-690,550 were studied in medically stable patients with psoriasis; the results suggest the potential for effectiveness of JAK3-mediated immunosuppression in this T-cell-mediated condition. In this phase 1, randomized, dose escalation, double-blind study, each of the six CP-690,550 dosage cohorts (oral administration of 5, 10, 20, 30, and 50 mg two times-daily (b.i.d.) and 60 mg once-daily (q.d.)) had a concurrent, parallel, placebo control. Cohorts were conducted sequentially except for the 60 mg q.d. and 50 mg b.i.d. cohorts, which were conducted concurrently. Patients received treatment for 14 days and follow-up assessments were conducted 4, 7, 14, and 28 days after the last dose and until any clinically relevant abnormalities relating to the study were resolved. Biopsies were conducted at baseline and at day 14. Institutional Review Board approval was obtained from the Human Volunteers Research Committee at Arkansas Research, and written informed consent was obtained from each patient. The Declaration of Helsinki protocols were followed. A total of 59 Caucasian patients (aged 23–63 years) with at least one evaluable plaque of psoriasis were enrolled in the placebo (n=13) or the CP-690,550 groups: five each at 5 mg b.i.d. and 10 mg b.i.d., 10 at 20 mg b.i.d., nine each at 30 mg b.i.d. and 60 mg q.d., and eight at 50 mg b.i.d. (CONSORT details for each cohort are provided in Figure S1). Index psoriasis lesions were assessed for erythema, induration, and scaling using a Psoriatic Lesion Severity Sum (PLSS) score; a total score of 5–12 and an induration score of 2–4 were required at baseline. Results showed a dose-dependent decrease (improvement) in the least squares mean (LSM) of percentage change in PLSS score from baseline to day 14 for all CP-690,550 doses except 5 mg b.i.d. (P<0.01 vs placebo) (Figure 1). Three out of eight patients in the highest dose group (50 mg b.i.d.) reduced their PLSS scores to 0 (from baseline scores of 4–6) on day 14. These results were also reflected in an analysis of the change from baseline in PLSS component scores (erythema, induration, and scaling) (data not shown). Physician's Global Assessment (PGA) scores for the index lesions at baseline were similar across the groups (mean±SD values 2.8±0.8–4.0±0.9, indicating moderate or mild-to-moderate disease). The LSM increase (signifying improvement) from baseline to day 14 in PGA scores was significantly greater (P<0.01) in the CP-690,550 30 and 50 mg b.i.d. groups than in the placebo group. The percentage of patients with a day 14 PGA response (defined as ‘almost clear’ or ‘clear’ and 2-point PGA score improvement from baseline) was significantly higher (P<0.05) in the CP-690,550 50 mg b.i.d. group than in the placebo group. A total of six patients receiving CP-690,550 (5 mg b.i.d., n=1; 20 mg b.i.d., n=1; 30 mg b.i.d., n=4) and two patients receiving placebo had evaluable biopsies at day 14. When compared with baseline biopsies, a marked histological improvement (to normal or near normal) was seen in three of the biopsied patients receiving CP-690,550, all at the higher dose of 30 mg b.i.d. A clear histological improvement was observed in one of the biopsied patients receiving placebo. The remaining biopsied patients showed minimal or no changes compared with baseline. Examples of immunohistochemistry of biopsies from patients who received placebo or CP-690,550 30 mg b.i.d. are shown in Figure 2. In all patients with biopsies, baseline keratin 16 (K16, a keratinocyte growth-activation marker) expression was normal (score of 0 on the 5-point (0–4) scale) or near normal (score of 1) in the nonlesional biopsy but highly abnormal (score of 4) in the lesional biopsy. At day 14, lesional biopsy K16 expression had improved to normal or near normal in three of the four patients in the 30 mg b.i.d. group (including the patient shown in Figure 2), had improved (to a score of 2) in 1 of the 2 placebo recipients, and remained unchanged in the four other patients who underwent skin biopsy. Improvement in the 30 mg b.i.d. group was also evidenced by a day 14 decrease from baseline in mean±SD lesion thickness (−157±165 microns) and in the number of cells positive for tested biomarkers per linear millimeter of lesion biopsy: CD3+ (−40±103 epidermal, −35±94 dermal), CD8+ (−57±20 epidermal, −33±91 dermal), CD11c+ (−64±63 epidermal, −181±189 dermal), CD25+ (−36±24 epidermal, −45±55 dermal), and CD83+ (−16±11 epidermal, −15±9 dermal). There were 16 adverse events (AEs) in 10 patients, most commonly headache (n=5) and nausea (n=3); all but three occurred in patients receiving CP-690,550. All were mild except for moderate worsening psoriasis (n=1). There was one serious AE, mild atrial fibrillation (10 mg b.i.d. group), which was not considered treatment-related. Overall, there was no evidence of dose–response in AE occurrence, and no dose-related or clinically significant changes in vital signs or electrocardiograms. Total cholesterol in the 30 and 50 mg b.i.d. groups, low-density lipoprotein cholesterol in the 30 mg b.i.d. group, and triglycerides in the 50 mg b.i.d. group were elevated relative to placebo. Other abnormal safety laboratory tests showed no clear relationship to CP-690,550 dose. These findings demonstrate that JAK3 inhibition may provide a viable mechanism of action for the treatment of psoriasis, and to our knowledge this is previously unreported. Through inhibition of JAK3, CP-690,550 is thought to suppress the intracellular signal transduction from the common γ chain receptors for the cytokines IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 (Borie et al 2004), thereby disrupting the activation, proliferation, and homeostasis of helper and cytotoxic T lymphocytes. The inhibition of IL-15 activity may be of particular relevance because IL-15 shows high levels of expression and enhanced binding activity in psoriasis lesions, and is also associated with increases in the apoptotic resistance of keratinocytes (Ruckert et al 2000). The sample size of this study was relatively small, no adjustments were made for multiple comparisons due to the exploratory nature of the analyses, and placebo patients across the six cohorts were combined into a single group for all analyses. Despite these limitations, this study demonstrated substantial improvement in psoriatic lesion severity suggesting that CP-690,550 is a potent immunosuppressant. Further studies with CP-690,550 in immune-mediated disorders are warranted. James G. Krueger received a research grant from Pfizer Inc., to do the histology analysis that is a part of this article. Mary G. Boy, Cunshan Wang, Bethanie E. Wilkinson, Vincent Fung-Sing Chow, Alan T. Clucas, Samuel H. Zwillich, and Gary Chan, are employees of Pfizer Inc., Mary G. Boy, Cunshan Wang, Bethanie E. Wilkinson, Vincent Fung-Sing Chow, Alan T. Clucas, Samuel H. Zwillich, and Gary Chan are eligible to receive Pfizer stock options. Anderson S. Gaweco and Paul S. Changelian were employees of Pfizer at the time of this research. This study was sponsored by Pfizer Inc. Editorial support for this article was provided by Dean Clarke at Complete Medical Communications. The clinical phase of the study was conducted at Arkansas Research, 1207 Rebsamen Park Road, Little Rock, Arkansas, 72202 USA. SUPPLEMENTARY MATERIAL Figure S1. CONSORT details. Patient flow for each cohort throughout the study.